Diabetes Drugs Market to Reach USD 153.4 Billion by 2033

Trishita Deb
Trishita Deb

Updated · May 22, 2024


At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.


The Global Diabetes Drugs Market is poised for significant growth, with its size expected to reach USD 153.4 billion by 2033, up from USD 69.1 billion in 2023, growing at a compound annual growth rate (CAGR) of 8.6% during the forecast period from 2024 to 2033. Several factors contribute to this growth trajectory. The increasing prevalence of diabetes worldwide, particularly type 2 diabetes, is a primary driver. According to the International Diabetes Federation, the number of adults living with diabetes is projected to rise from 537 million in 2021 to 783 million by 2045. Additionally, advancements in diabetes medication, such as the introduction of GLP-1 receptor agonists and SGLT-2 inhibitors, provide effective alternatives to traditional treatments, further propelling market growth.

Recent developments in the market include the launch of new drugs and formulations. For instance, in January 2024, Glenmark Pharmaceuticals introduced Lirafit, a biosimilar of the widely-used anti-diabetic drug Liraglutide, in India. Moreover, companies like Akums Drugs and Pharmaceuticals have developed novel combination therapies targeting the elderly population with type 2 diabetes, enhancing treatment efficacy and patient compliance.

However, the market faces challenges, such as the high cost of diabetes drug therapies, which can be a significant barrier, particularly in developing and underdeveloped regions. Despite these challenges, the growing focus on diabetes care, increasing awareness, and substantial R&D investments by key players are expected to sustain the market’s growth momentum. The North American region, driven by high obesity rates and a sedentary lifestyle, leads the market, with the U.S. holding the largest share due to its significant demand for insulin and other diabetes medications.

Key Takeaways

  • In 2023, the global diabetes drugs market generated USD 69.1 billion, forecasted to exceed USD 153.4 billion, growing at a CAGR of 8.3%.
  • The GLP-1 receptor agonists segment led the market in 2023 with a 32.6% share.
  • The type 2 diabetes segment held the largest market share in 2023 at 62.9%, due to higher global prevalence.
  • Subcutaneous route of administration dominated the market in 2023 with a 45.8% share.
  • Retail pharmacies secured the largest market share in 2023, accounting for 62.4% of sales due to competitive pricing.
  • North America accounted for a significant 51.3% share of the diabetes drugs market in 2023.
Diabetes Drugs Market Size
To learn more about this report – request a sample report PDF

Diabetes Drugs Statistics

  • The prevalence of Type 2 Diabetes in the US nearly tripled from 1980 to 2011.
  • Approximately 1 in 3 US adults are expected to develop diabetes in their lifetime.
  • The cost of Type 2 Diabetes Mellitus in 2012 was $245 billion.
  • Direct medical expenditures for Type 2 Diabetes in 2012 totaled $176 billion.
  • Only 36% of patients achieve glycemic control with current diabetes therapies.
  • An estimated 3.1 million US adults with Type 2 Diabetes were not taking medications in 2011.
  • The mean cost per inpatient admission for hypoglycemic events is $17,564.
  • The total direct medical cost of hypoglycemia during a 4-year study was $52,223,675.
  • A 1% weight loss in 1 year decreases healthcare costs by approximately $213 per patient.
  • Weight loss is associated with better adherence to antidiabetic medications.
  • There are as many as 14 classes of drugs available for Type 2 Diabetes.
  • Emerging therapies for Type 2 Diabetes include SGLT-2 inhibitors (Canagliflozin, dapagliflozin, empagliflozin) and GLP-1 agents (Exenatide, albiglutide, dulaglutide).
  • Technosphere insulin, known as Afrezza, is an emerging therapy for Type 2 Diabetes.
  • Canagliflozin received FDA approval in March 2013.
  • Dapagliflozin was approved by the FDA in January 2014.
  • Empagliflozin gained FDA approval in August 2014.
  • Monthly costs for Canagliflozin range from $324.51 to $348.81.
  • Monthly costs for Dapagliflozin range from $324.43 to $348.72.
  • Monthly costs for Empagliflozin range from $313.19 to $325.93.
  • Ozempic (Semaglutide): Sales in 2022 reached $8.713 billion. FDA approved on December 5, 2017, for type 2 diabetes. Costs $1,029 for a 1.5 mL subcutaneous solution.
  • Jardiance (Empagliflozin): Achieved $8.388 billion in 2022 sales. FDA approval on August 1, 2014. Treats type 2 diabetes, heart failure, and chronic kidney disease. Costs $570.48 for a month.
  • Trulicity (Dulaglutide): Generated $7.439 billion in 2022 sales. Approved by FDA on September 18, 2014, for type 2 diabetes. Priced at $930.88 per month.
  • Januvia (Sitagliptin): Earned $4.513 billion in 2022 sales. FDA approval on October 16, 2006. Used for type 2 diabetes. Costs approximately $613 for a 30-tablet supply.
  • Farxiga (Dapagliflozin): Achieved $4.381 billion in 2022 sales. FDA approved on January 8, 2014. Treats type 2 diabetes, heart failure, and chronic kidney disease. Priced at $623 per month.
  • Lantus (Insulin Glargine): Sales totaled $2.380 billion in 2022. FDA approved on April 20, 2000, for type 1 and type 2 diabetes. Costs $64-$77 for a 10 mL vial.
  • NovoRapid (Insulin Aspart): Recorded $2.259 billion in 2022 sales. FDA approved on June 7, 2000, for type 1 and type 2 diabetes. Priced at $157 for a 15 mL FlexPen.
  • Humalog (Insulin Lispro): Generated $2.060 billion in 2022 sales. FDA approved on June 14, 1996, for type 1 and type 2 diabetes. Costs $159.12 for a 5-pack of 3 mL KwikPens.
  • Trajenta (Linagliptin/Metformin): Achieved $1.846 billion in 2022 sales. FDA approval on May 2, 2021, for type 2 diabetes. Estimated annual cost is $931.
  • Victoza (Liraglutide): Earned $1.796 billion in 2022 sales. FDA approved on January 25, 2010, for type 2 diabetes. Priced at $543.51 for 2-pen or $815.27 for 3-pen package.
  • People with Type 2 diabetes using GLP-1 medicines and FreeStyle Libre technology together saw a significant improvement in HbA1c compared to those using GLP-1 alone.
  • GLP-1 medicines stimulate insulin release, lower blood sugar levels, reduce appetite, and support weight loss in people with Type 2 diabetes.
  • Adding FreeStyle Libre technology to GLP-1 therapy resulted in better glycemic control and greater reduction in HbA1c levels.
  • Real-world studies showed a –1.5% improvement in HbA1c after six months with GLP-1 and FreeStyle Libre combination therapy.
  • Another study demonstrated a –2.4% reduction in HbA1c with GLP-1 and FreeStyle Libre technology, compared to –1.7% with GLP-1 alone.
  • FreeStyle Libre continuous glucose monitoring systems provide real-time data on glucose levels, aiding adherence to therapy and lifestyle changes.
  • These findings support the combined use of GLP-1 medicines and FreeStyle Libre technology for improved management of Type 2 diabetes.

Emerging Trends

  • Rising Popularity of SGLT2 Inhibitors and GLP-1 Receptor Agonists: SGLT2 inhibitors and GLP-1 receptor agonists are becoming increasingly popular in diabetes treatment due to their dual benefits. Not only do these drugs effectively control blood sugar levels, but they also offer additional health benefits such as weight loss and cardiovascular protection. Their ability to address multiple health concerns makes them a preferred choice among healthcare providers and patients. The growing body of evidence supporting their efficacy is likely to further boost their adoption in clinical practice, making them central to diabetes management strategies.
  • Increased Focus on Biosimilar Insulin: The introduction of biosimilar insulin products is poised to revolutionize diabetes care by significantly reducing treatment costs and improving accessibility. This is particularly crucial for developing countries where the high cost of insulin has been a major barrier to effective diabetes management. Biosimilars offer the same therapeutic benefits as original insulin products but at a lower cost, making diabetes treatment more affordable for a larger population. This trend is expected to drive widespread adoption and enhance the overall management of diabetes on a global scale.
  • Technological Advancements in Drug Delivery: Innovations in drug delivery technologies are transforming diabetes management. Continuous glucose monitoring (CGM) systems and automated insulin delivery (AID) systems are at the forefront of these advancements. These technologies provide real-time monitoring and precise insulin delivery, which significantly improve blood glucose control and reduce the burden of diabetes management. Enhanced patient compliance and the ability to tailor treatments to individual needs are among the key benefits. As technology continues to evolve, these advanced systems are expected to become standard practice in diabetes care.
  • Growing Investment in R&D: Pharmaceutical companies are increasingly investing in research and development to discover new and more effective diabetes treatments. This includes the development of combination therapies and novel drug formulations that offer improved outcomes for patients. Significant financial resources are being allocated to explore innovative approaches and bring new drugs to market. These efforts are not only aimed at enhancing the efficacy of diabetes treatments but also at reducing side effects and improving patient quality of life. The surge in R&D investment underscores the commitment to advancing diabetes care.
  • Expansion of Oral Diabetes Medications: There is a growing emphasis on developing oral diabetes medications to reduce the dependency on injections, which can be a barrier for many patients. New oral formulations of GLP-1 receptor agonists and SGLT2 inhibitors are being developed and have already received regulatory approval. These oral medications offer a more convenient and less invasive option for diabetes management, potentially increasing patient adherence to treatment regimens. As these medications become more widely available, they are expected to play a significant role in the future of diabetes therapy, providing patients with more choices and better quality of life.

Use Cases

  • Type 2 Diabetes Management: The majority of diabetes drug prescriptions are for type 2 diabetes, which is more prevalent globally. Commonly prescribed drugs for managing blood sugar levels in these patients include metformin, SGLT2 inhibitors, and DPP-4 inhibitors. These medications help in controlling blood glucose by enhancing insulin sensitivity, reducing glucose production in the liver, and promoting glucose excretion via urine. In India, approximately 77 million adults over the age of 18 suffer from type 2 diabetes, highlighting the significant demand for effective diabetes management solutions in the country.
  • Type 1 Diabetes Treatment: Insulin therapy remains the cornerstone of treatment for type 1 diabetes. Patients require lifelong administration of insulin, with long-acting insulins such as insulin glargine and rapid-acting insulins like insulin aspart being essential for maintaining blood glucose levels. These therapies mimic the natural insulin release in the body, thus providing better glucose control. In India, about 95,600 children under 14 years of age have type 1 diabetes, necessitating accessible and reliable insulin therapies to manage their condition effectively.
  • Geriatric Diabetes Care: Older adults with diabetes often require specialized treatment plans due to the presence of comorbidities and age-related factors. Fixed-dose combination therapies are particularly beneficial for this demographic, as they simplify medication regimens and improve adherence. These combination therapies can include medications that control blood sugar, blood pressure, and cholesterol simultaneously. Such comprehensive treatment approaches are crucial for minimizing complications and enhancing the quality of life for elderly diabetes patients.
  • Pediatric Diabetes Management: Recent approvals of oral diabetes medications for pediatric patients are significantly improving treatment adherence and outcomes among young patients with type 2 diabetes. For instance, FDA-approved medications like Synjardy (empagliflozin and metformin hydrochloride) have made it easier for pediatric patients to manage their blood glucose levels without the need for injections. This development is particularly important as it encourages consistent medication use, thereby better controlling the condition in young patients and reducing long-term health risks.
  • Hospital and Clinical Settings: Diabetes drugs are extensively used in hospital settings to manage both acute and chronic cases of diabetes. Hospitals provide a controlled environment with skilled healthcare professionals and comprehensive care facilities, making them primary sites for diabetes treatment. In these settings, patients can receive tailored treatment plans, including insulin administration, oral medications, and continuous glucose monitoring. This integrated approach ensures better management of diabetes complications and promotes overall patient health.
  • Ambulatory Clinics: Ambulatory clinics are increasingly important for diabetes management due to their accessibility and ability to provide continuous care and monitoring for diabetes patients. These clinics offer convenience and personalized care, which is essential for managing chronic conditions like diabetes. Ambulatory clinics have become the fastest-growing segment in the diabetes drug market, driven by rising patient awareness and the need for ongoing diabetes management. They provide essential services such as regular check-ups, medication adjustments, and lifestyle counseling, contributing to better long-term health outcomes for diabetes patients.


The diabetes drugs market is projected to grow significantly, driven by the rising prevalence of diabetes globally and continuous advancements in treatment options. Key trends include the increasing popularity of SGLT2 inhibitors and GLP-1 receptor agonists due to their dual benefits in controlling blood sugar and providing cardiovascular protection. Additionally, the introduction of biosimilar insulin products is expected to make diabetes treatment more affordable, particularly in developing countries. Technological innovations in drug delivery, such as continuous glucose monitoring and automated insulin delivery systems, are enhancing diabetes management. These factors, coupled with substantial R&D investments, are anticipated to sustain the market’s growth momentum​.

Trishita Deb

Trishita Deb

Trishita has more than 7 years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.